Please try another search
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Name | Age | Since | Title |
---|---|---|---|
Amos Bar Shalev | 71 | 2008 | Independent Director |
Roger D. Kornberg | 77 | 2008 | Chairman of Scientific Advisory Board |
Aharon Schwartz | 81 | 2014 | Independent Director |
Charles J. Arntzen | 83 | 2016 | Member of Scientific Advisory Board |
Gwen A. Melincoff | 72 | 2020 | Independent Director |
Alexander Levitzki | 84 | - | Member of Scientific Advisory Board |
Dror Bashan | 57 | 2019 | President, CEO & Director |
Pol F. Boudes | 67 | 2020 | Independent Director |
Shmuel Ben-Zvi | 64 | 2022 | Independent Director |
Eliot Richard Forster | 58 | 2023 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review